ArriVent BioPharma (AVBP) Competitors $26.63 +0.60 (+2.31%) (As of 12/24/2024 03:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVBP vs. RYTM, MLTX, JANX, MRUS, XENE, ZLAB, ACAD, MOR, TWST, and EWTXShould you be buying ArriVent BioPharma stock or one of its competitors? The main competitors of ArriVent BioPharma include Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), Janux Therapeutics (JANX), Merus (MRUS), Xenon Pharmaceuticals (XENE), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Twist Bioscience (TWST), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. ArriVent BioPharma vs. Rhythm Pharmaceuticals MoonLake Immunotherapeutics Janux Therapeutics Merus Xenon Pharmaceuticals Zai Lab ACADIA Pharmaceuticals MorphoSys Twist Bioscience Edgewise Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation. Do institutionals and insiders believe in RYTM or AVBP? 9.5% of ArriVent BioPharma shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate RYTM or AVBP? Rhythm Pharmaceuticals presently has a consensus price target of $66.90, indicating a potential upside of 19.79%. ArriVent BioPharma has a consensus price target of $36.80, indicating a potential upside of 38.19%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RYTM or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. ArriVent BioPharma's return on equity of -43.89% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% ArriVent BioPharma N/A -43.89%-29.67% Does the MarketBeat Community prefer RYTM or AVBP? Rhythm Pharmaceuticals received 279 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 67.05% of users gave Rhythm Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes29567.05% Underperform Votes14532.95% ArriVent BioPharmaOutperform Votes16100.00% Underperform VotesNo Votes Does the media prefer RYTM or AVBP? In the previous week, Rhythm Pharmaceuticals had 22 more articles in the media than ArriVent BioPharma. MarketBeat recorded 22 mentions for Rhythm Pharmaceuticals and 0 mentions for ArriVent BioPharma. Rhythm Pharmaceuticals' average media sentiment score of 0.79 beat ArriVent BioPharma's score of -0.55 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Rhythm Pharmaceuticals Positive ArriVent BioPharma Negative Which has preferable earnings & valuation, RYTM or AVBP? ArriVent BioPharma has lower revenue, but higher earnings than Rhythm Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$112.53M30.50-$184.68M-$4.33-12.90ArriVent BioPharmaN/AN/A-$69.33MN/AN/A SummaryArriVent BioPharma beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get ArriVent BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AVBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVBP vs. The Competition Export to ExcelMetricArriVent BioPharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$897.35M$6.71B$5.22B$9.27BDividend YieldN/A3.00%5.12%4.30%P/E RatioN/A10.5487.3417.27Price / SalesN/A195.821,166.41119.73Price / CashN/A57.1443.2337.83Price / Book-5.565.164.834.93Net Income-$69.33M$151.58M$120.46M$225.34M7 Day Performance3.38%4.12%2.84%4.14%1 Month Performance-3.16%-3.99%19.70%1.16%1 Year PerformanceN/A10.33%30.57%16.98% ArriVent BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVBPArriVent BioPharma0.7149 of 5 stars$26.63+2.3%$36.80+38.2%N/A$897.35MN/A0.0040RYTMRhythm Pharmaceuticals4.1191 of 5 stars$56.43+0.6%$66.90+18.6%+20.5%$3.47B$112.53M-13.03140Analyst ForecastMLTXMoonLake Immunotherapeutics1.6197 of 5 stars$52.00-0.3%$81.43+56.6%-12.4%$3.32BN/A-40.312JANXJanux Therapeutics3.7192 of 5 stars$56.45-0.7%$89.90+59.3%+431.1%$2.96B$13.05M-48.2530Positive NewsMRUSMerus2.3034 of 5 stars$42.84+2.4%$85.64+99.9%+56.7%$2.93B$43.95M-10.8537XENEXenon Pharmaceuticals2.884 of 5 stars$38.28-0.9%$56.00+46.3%-13.9%$2.92B$9.43M-13.57251ZLABZai Lab2.0083 of 5 stars$26.50-0.8%$55.00+107.5%+6.3%$2.88B$355.75M-9.572,175ACADACADIA Pharmaceuticals3.9376 of 5 stars$17.19+1.9%$25.60+48.9%-45.6%$2.86B$929.24M22.04510Positive NewsMORMorphoSys0.1343 of 5 stars$18.96flat$14.33-24.4%N/A$2.86B$238.28M-5.45730TWSTTwist Bioscience2.7821 of 5 stars$48.08+0.3%$51.90+7.9%+33.0%$2.85B$312.97M-13.36990EWTXEdgewise Therapeutics2.5734 of 5 stars$29.91-2.8%$43.17+44.3%+217.5%$2.83BN/A-19.9460 Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Janux Therapeutics Competitors Merus Competitors Xenon Pharmaceuticals Competitors Zai Lab Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Twist Bioscience Competitors Edgewise Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVBP) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
